What is NorthEast BioLab?
NorthEast BioLab operates as a premier bioanalytical contract research organization, providing critical support for the development of small molecules, biologics, and advanced cell and gene therapies. With a legacy spanning over two decades, the firm maintains a sophisticated infrastructure capable of executing complex pharmacokinetics studies, immunogenicity assays, and biomarker testing. By integrating high-throughput technologies such as LC-MS, ELISA, and flow cytometry, NorthEast BioLab ensures that its clients meet stringent GLP and regulatory standards. The company serves as a vital link in the drug development value chain, offering the technical precision required to navigate the rigorous demands of modern clinical research and regulatory compliance.
How much funding has NorthEast BioLab raised?
NorthEast BioLab has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in NorthEast BioLab
PPP
Public-Private Partnership
What's next for NorthEast BioLab?
With the recent infusion of capital, NorthEast BioLab is poised to accelerate its strategic growth initiatives, likely focusing on the expansion of its high-complexity testing capabilities and the modernization of its laboratory facilities. As the demand for specialized bioanalytical services continues to rise in the wake of rapid innovation in gene therapy, the company is expected to deepen its market penetration. Future efforts will likely prioritize the integration of automated analytical workflows and the expansion of its footprint to better serve the evolving needs of biotech innovators. This late-stage financing provides the necessary runway to solidify its status as a market leader in the CRO landscape, ensuring long-term operational excellence and sustained competitive advantage.
See full NorthEast BioLab company page
